US2007225342A1PendingUtilityA1

Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor

Individually held — no corporate assignee on recordPriority: Sep 20, 1993Filed: Jun 4, 2007Published: Sep 27, 2007
Est. expirySep 20, 2013(expired)· nominal 20-yr term from priority
Inventors:David J. Bova
A61K 31/455A61P 3/10A61K 31/44A61K 9/2054A61P 3/06A61K 9/2027A61K 9/2077A61P 7/00
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night.

Claims

exact text as granted — not AI-modified
1 . (canceled)  
     
     
         2 . (canceled)  
     
     
         3 . (canceled)  
     
     
         4 . (canceled)  
     
     
         5 . (canceled)  
     
     
         6 . (canceled)  
     
     
         7 . (canceled)  
     
     
         8 . (canceled)  
     
     
         9 . (canceled)  
     
     
         10 . (canceled)  
     
     
         11 . (canceled)  
     
     
         12 . (canceled)  
     
     
         13 . A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the step of: 
 dosing the hyperlipidemic with a sustained release oral solid dosage form comprising about 500 mg nicotinic acid once per day and wherein the antihyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the antihyperlipidemic's HDL cholesterol is increased.    
     
     
         14 . The method according to  claim 13 , wherein the hyperlipidemic is dosed at night or in the evening.  
     
     
         15 . A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the step of: 
 dosing the hyperlipidemic with a sustained release oral solid dosage form comprising about 750 mg nicotinic acid once per day and wherein the antihyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the antihyperlipidemic's HDL cholesterol is increased.    
     
     
         16 . The method according to  claim 15 , wherein the hyperlipidemic is dosed at night or in the evening.  
     
     
         17 . A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the step of: 
 dosing the hyperlipidemic with a sustained release oral solid dosage form comprising about 1000 mg nicotinic acid once per day and wherein the antihyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the antihyperlipidemic's HDL cholesterol is increased.    
     
     
         18 . The method according to  claim 17 , wherein the hyperlipidemic is dosed at night or in the evening.  
     
     
         19 . A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the step of: 
 dosing the hyperlipidemic with a sustained release oral solid dosage form comprising about 2000 mg nicotinic acid once per day and wherein the antihyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the antihyperlipidemic's HDL cholesterol is increased.    
     
     
         20 . The method according to  claim 19 , wherein the hyperlipidemic is dosed at night or in the evening.  
     
     
         21 . The method according to claims  13  or  14 , wherein the sustained release oral solid dosage form is administered to the hyperlipidemic with food.  
     
     
         22 . The method according to claims  15  or  16 , wherein the sustained release oral solid dosage form is administered to the hyperlipidemic with food.  
     
     
         23 . The method according to claims  17  or  18 , wherein the sustained release oral solid dosage form is administered to the hyperlipidemic with food.  
     
     
         24 . The method according to claims  19  or  20 , wherein the sustained release oral solid dosage form is administered to the hyperlipidemic with food.

Join the waitlist — get patent alerts

Track US2007225342A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.